Cyclin D1 expression and novel mutational findings in Rosai‐Dorfman disease

Rosai‐Dorfman disease (RDD) is an enigmatic histiocytic disorder classically diagnosed by a distinctive combination of pathological features: emperipolesis, or migration of intact haematological cells through the voluminous cytoplasm of lesional histiocytes, and expression of S100 by these histiocytes. The pathogenesis has long been elusive until the recent detection of recurrent and mutually exclusive mutations in several oncogenes in the mitogen‐activated protein kinase (MAPK) pathway. Based on these findings, we investigated a cohort of 21 RDD patients and found that the lesional histiocytes in 86% (18/21) of patients exhibited strong and diffuse nuclear Cyclin D1 expression, which not only may provide a diagnostic marker for this sometimes pathologically challenging disease, but also probably reflects constitutive MAPK pathway activation because we additionally identified phosphorylated‐ERK expression in 90% (19/21) of cases. Further, we performed massively parallel sequencing on a subset (6/18) of the CyclinD1 positive cases, identifying several mutations that have not been previously reported in RDD. Taken together, our findings bolster the concept of RDD as a disease of MAPK activation in a substantial percentage of cases and enhance the current understanding of the pathogenesis of RDD.

[1]  Marilyn M. Li,et al.  SETD2 mutations in primary central nervous system tumors , 2018, Acta neuropathologica communications.

[2]  J. Manning,et al.  Focal Rosai–Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation , 2018, Modern Pathology.

[3]  S. Shrikhande,et al.  Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview , 2018, Current genomics.

[4]  S. Vicent,et al.  KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target , 2018, Molecular Cancer.

[5]  C. Fletcher,et al.  Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling , 2018, Modern Pathology.

[6]  J. Jagannathan,et al.  Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib. , 2017, The New England journal of medicine.

[7]  Lin Sun,et al.  Cyclin D1 expression by histiocytes may mimic cyclin D1-positive proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma. , 2017, Pathology, research and practice.

[8]  Joseph D Khoury,et al.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease , 2017, Modern Pathology.

[9]  G. Pinkus,et al.  Cyclin D1 Is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations , 2017, The American journal of surgical pathology.

[10]  A. Tripathi,et al.  ICUS/CCUS/CHIP: basics & beyond , 2017, Expert review of hematology.

[11]  O. Abdel-Wahab,et al.  Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. , 2017, Hematology/oncology clinics of North America.

[12]  I. Tabbara,et al.  Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances. , 2017, Anticancer research.

[13]  D. Cooper,et al.  The NF1 somatic mutational landscape in sporadic human cancers , 2017, Human Genomics.

[14]  Monia Magliozzi,et al.  Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome , 2017, Human mutation.

[15]  C. Classen,et al.  The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches , 2016, Klinische Pädiatrie.

[16]  C. Hutter,et al.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies , 2016, ImmunoTargets and therapy.

[17]  P. Gimotty,et al.  A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia , 2016, PloS one.

[18]  B. Reva,et al.  MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking , 2014, Clinical Cancer Research.

[19]  Larissa V Furtado,et al.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.

[20]  K. Gatter,et al.  Immunohistological recognition of cyclin D1 expression by non‐lymphoid cells among lymphoid neoplastic cells , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[22]  M. Borrello,et al.  TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells , 2011, Oncogene.

[23]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[24]  A. Bagg,et al.  Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma. , 2010, American journal of clinical pathology.

[25]  Sarah Edkins,et al.  Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.

[26]  X. Estivill,et al.  Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients , 2003, Journal of medical genetics.

[27]  H. Stöhr,et al.  A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. , 1995, Human molecular genetics.

[28]  A. Paller,et al.  Langerhans cell histiocytosis: A neoplastic disorder driven by Ras‐ERK pathway mutations , 2018, Journal of the American Academy of Dermatology.